Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis

Michael Kreuter; David J Lederer; Vincent Cottin; Nicolas Kahn; Brett Ley; Carlo Vancheri; Derek Weycker; Mark Atwood; Klaus-Uwe Kirchgaessler; Christopher J Ryerson

doi:10.1183/13993003.01188-2019

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis

Eur Respir J. 2019 Dec 12;54(6):1901188. doi: 10.1183/13993003.01188-2019. Print 2019 Dec.

Authors

Affiliations

¹ Center for Interstitial and Rare Lung Diseases, Pneumonology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany michael.kreuter@med.uni-heidelberg.de.
² Depts of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, NY, USA.
³ Dept of Respiratory Medicine, Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Claude Bernard University Lyon 1, UMR754, Lyon, France.
⁴ Center for Interstitial and Rare Lung Diseases, Pneumonology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany.
⁵ Dept of Medicine, University of California, San Francisco, San Francisco, CA, USA.
⁶ Dept of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
⁷ Policy Analysis Inc. (PAI), Brookline, MA, USA.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ Dept of Medicine, University of British Columbia, Vancouver, BC, Canada.

Abstract

This post hoc exploratory analysis found no clear associations between frequently used concomitant medication combinations and disease progression in 1450 patients with IPF enrolled in phase III trials, but several combinations may require further study. http://bit.ly/2ZzyMXR

Publication types

Letter

MeSH terms

Comorbidity
Drug Interactions
Drug Therapy, Combination / methods
Humans
Idiopathic Pulmonary Fibrosis / drug therapy*
Randomized Controlled Trials as Topic